Polypeptides from non-typeable
Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae , such as otitis media.
1. An immunogenic composition comprising an effective amount of (a) an isolated, immunogenic polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1842 from Haemophilus influenzae strain 86-028NP, or the amino acid sequence of SEQ ID NO: 1842 that lacks a signal sequence; (b) a pharmaceutically acceptable carrier, and (c) an adjuvant.
2. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1842.
3. An immunogenic comprising an effective amount of (a) an isolated polypeptide that comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1842; (b) a pharmaceutically acceptable carrier, and (c) an adjuvant.
4. The composition of claim 1 , wherein the adjuvant comprises an aluminium salt.
5. The composition of claim 2 , wherein the adjuvant comprises an aluminium salt.
6. The composition of claim 3 , wherein the adjuvant comprises an aluminium salt.
7. The composition of claim 1 , wherein the adjuvant is an oil emulsion.
8. The composition of claim 2 , wherein the adjuvant is an oil emulsion.
9. The composition of claim 3 , wherein the adjuvant is an oil emulsion.
10. The composition of claim 7 , wherein the adjuvant is MF59.
11. The composition of claim 8 , wherein the adjuvant is MF59.
12. The composition of claim 9 , wherein the adjuvant is MF59.
13. The composition of claim 7 , wherein the adjuvant is Complete Freund's adjuvant or Incomplete Freund's adjuvant.
14. The composition of claim 8 , wherein the adjuvant is Complete Freund's adjuvant or Incomplete Freund's adjuvant.
15. The composition of claim 9 , wherein the adjuvant is Complete Freund's adjuvant or Incomplete Freund's adjuvant.